Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00460460
NCT00460460
Terminated
Phase 1

A Phase I, Open-label, Dose Escalation Study to Assess the Safety, Tolerability & Pharmacokinetics of AZD4877 Administered Once Weekly in Adult Patients With Recurrent or Refractory AML, PH Negative ALL, NHL or MN

AstraZeneca2 sites in 2 countries75 target enrollmentMarch 2007
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsLymphoma
DrugsAZD4877

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Lymphoma
Sponsor
AstraZeneca
Enrollment
75
Locations
2
Status
Terminated
Last Updated
15 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a weekly basis in these diseases.

Registry
clinicaltrials.gov
Start Date
March 2007
End Date
August 2007
Last Updated
15 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patients with AML, a certain type of ALL, NHL and MM
  • •certain types of cancer of the lymph nodes
  • •certain types of leukemias (blood cancers)
  • •disease has or will fail with other treatments
  • •relatively good overall health other than your cancer

Exclusion Criteria

  • •poor bone marrow function (not producing enough blood cells)
  • •serious heart conditions
  • •poor liver or kidney function

Outcomes

Primary Outcomes

Not specified

Study Sites (2)

Loading locations...

Similar Trials

Terminated
Phase 1
Safety and Tolerability Study of AZD7762 in Combination With GemcitabineCancerSolid TumorsAdvanced Solid Malignancies
NCT00937664AstraZeneca24
Terminated
Phase 1
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918Cancer,Solid TumorsAdvanced Solid Malignancies
NCT00733031AstraZeneca75
Completed
Phase 1
Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid TumorsNeoplasms
NCT00389389AstraZeneca75
Completed
Phase 1
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid TumoursNeoplasms
NCT02952248Boehringer Ingelheim110
Recruiting
Phase 1
Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid MalignanciesAdvanced Solid Malignancies
NCT02347228Oneness Biotech Co., Ltd.30